Dr. Mandeep Singh Dhalla, MD

Dr. Dhalla practices at Retina Group Of Florida in Fort Lauderdale, Florida.

Dr. Dhalla's NPI, 1457389447, was assigned on June 29, 2006. Dr. Dhalla graduated from University of Miami, Miller School of Medicine in 2001. Dr. Dhalla holds Florida license ME98620.

Dr. Dhalla's primary practice is Retina Group of Florida, at 6333 N Federal Hwy Ste 300 Suite 300, Fort Lauderdale, FL 33308. The practice phone is (954) 776-6880.

Dr. Dhalla's primary practice is Retina Group Of Florida in Fort Lauderdale, Florida. Dmand AI also links Dr. Dhalla to 1 medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dhalla practices. Vendor and product names are available with a free account.

Retina specialist is Dr. Dhalla's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Dhalla is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Dhalla's licenses on file in 2 states: Florida and Michigan.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Dhalla treats.

CMS data shows 16,503 Medicare services from Dr. Dhalla across 12 procedure codes in 2024, for 831 Medicare patients. Medicare paid $2,123,274 for them. Every service was in an office.

CMS counts 831 Medicare patients who saw Dr. Dhalla in 2024. The largest group is 65 to 74, with 322 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dhalla's median patient age at 73, with 53% women.

In 2024, Dr. Dhalla wrote 136 Medicare Part D claims for 56 patients. 62% of them were for generic drugs. CMS names the drug for 97 of them, across 4 drugs with 11 or more claims each, at $4,914 in total drug cost. In 2023, CMS named 103 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dhalla for performance year 2024, reported as part of a group. Dr. Dhalla accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Dhalla in 2007. The most frequent topics are Fluorescein Angiography, Visual Acuity and Choroidal Neovascularization. Dr. Dhalla has published most often in Retina. Dr. Dhalla's most frequent co-authors are Gaurav K. Shah, MD, Aldo Fantin, MD and Arghavan Almony, MD.

CMS Open Payments shows 149 general payments to Dr. Dhalla from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 82% of the total. Genentech, Inc. paid the most, $72,020.

Dmand AI lists 3 awards for Dr. Dhalla.

Dr. Dhalla graduated from University of Miami, Miller School of Medicine in 2001. Dr. Dhalla is a member of AAO and ASRS.

Dr. Dhalla is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.